| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/09/2010 | CA2291065C Raf kinase inhibitors |
| 02/09/2010 | CA2287469C Interactive system for presenting and eliminating substances |
| 02/09/2010 | CA2286614C Plant extracts for the treatment of increased bone resorption |
| 02/09/2010 | CA2268403C Anthranilic acid derivatives as multi drug resistance modulators |
| 02/09/2010 | CA2205910C Plasmids suitable for il-2 expression |
| 02/09/2010 | CA2201863C Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors |
| 02/09/2010 | CA2196315C Treatment of cancer using hsv mutant |
| 02/09/2010 | CA2192092C Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors |
| 02/06/2010 | CA2660507A1 Targeted nanoparticles for cancer diagnosis and treatment |
| 02/04/2010 | WO2010014975A2 Use of microrna signatures for assessing risk levels of neuroblastoma patients |
| 02/04/2010 | WO2010014933A2 Psma-binding agents and uses thereof |
| 02/04/2010 | WO2010014841A1 Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof |
| 02/04/2010 | WO2010014784A2 Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| 02/04/2010 | WO2010014751A2 Monoclonal antibody zt/2f2 in targeted therapy of cancers overexpressing the ron receptor tyrosine kinase |
| 02/04/2010 | WO2010014611A1 Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds |
| 02/04/2010 | WO2010014253A2 Ant4 inhibitor compounds and methods of use thereof |
| 02/04/2010 | WO2010014240A2 Novel bioactive small molecules derived from sea sponges |
| 02/04/2010 | WO2010014176A2 Preparation method of biodegradable micro-particles containing drugs |
| 02/04/2010 | WO2010014022A1 A process for the preparation of imatinib |
| 02/04/2010 | WO2010013836A1 Active targeting type polymeric micelle carrying drug enclosed therein and medicinal composition |
| 02/04/2010 | WO2010013815A1 Composition for inhibiting expression of target gene |
| 02/04/2010 | WO2010013769A1 Crystal of thiazolidinedione compound, and process for production thereof |
| 02/04/2010 | WO2010013768A1 Crystal of thiazolidinedione compound, and process for production thereof |
| 02/04/2010 | WO2010013762A1 Metastin derivative and use thereof |
| 02/04/2010 | WO2010013633A1 Methods for prediction of rb status and sensitivity to plk1 inhibitor of cell |
| 02/04/2010 | WO2010013595A1 (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
| 02/04/2010 | WO2010013494A1 Pharmaceutical composition comprising botulinum neurotoxin preparation incapable of being synaptically transported, and use thereof |
| 02/04/2010 | WO2010013485A1 Melk epitope peptides and vaccines containing the same |
| 02/04/2010 | WO2010013168A1 3',6-substituted indirubins and their biological applications |
| 02/04/2010 | WO2010013037A1 1,2,4-oxadiazole substituted piperidine and piperazine derivatives as smo antagonists |
| 02/04/2010 | WO2010013011A1 P53 tumor suppressor protein activating |
| 02/04/2010 | WO2010012965A2 Combination of a tlr3 ligand and a chemotherapy agent which acts on the intrinsic “apoptosis” pathway in the treatment of cancer |
| 02/04/2010 | WO2010012912A2 Use of a soluble form of hla-g in the treatment of abnormal b-lymphocyte proliferation |
| 02/04/2010 | WO2010012911A1 Antibodies binding to adrenomedullin receptors and uses thereof as drugs |
| 02/04/2010 | WO2010012780A1 Vaccine against hpv |
| 02/04/2010 | WO2010012777A1 THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT |
| 02/04/2010 | WO2010012761A1 Dimeric derivatives of artemisinin and application in anti-cancer therapy |
| 02/04/2010 | WO2010012747A1 New compounds |
| 02/04/2010 | WO2010012745A2 Benzimidazoles |
| 02/04/2010 | WO2010012651A2 Composition useful for the prevention or reduction of the progression of prostate cancer |
| 02/04/2010 | WO2010012611A1 Compound with serotoninergic activity, process for preparing it and pharmaceutical composition comprising it |
| 02/04/2010 | WO2010012466A1 Antitumor properties of no modified protease inhibitors |
| 02/04/2010 | WO2010012438A2 Recombinant preparation of bromelain inhibitors and bromelain inhibitor precursor |
| 02/04/2010 | WO2010012399A1 Indolylamides as modulators of the ep<sb>2</sb> receptor |
| 02/04/2010 | WO2010012396A1 5,6 substituted benzamide derivatives as modulators of the ep<sb>2 </sb>receptor |
| 02/04/2010 | WO2010012345A1 Imidazothiadiazoles derivatives |
| 02/04/2010 | WO2010012319A1 Use of opioids or opioid mimetics for the treatment of resistant cancer patients |
| 02/04/2010 | WO2010012222A1 Peptidyl boric aicd and its ester derivatives, synthesis and use thereof |
| 02/04/2010 | WO2010012131A1 The usage of medicinal composition containing oil of zedoary turmeric in manufacture of medicaments |
| 02/04/2010 | WO2010012088A1 Apparatus and method for loading and transporting containers |
| 02/04/2010 | WO2010012037A1 6-substituted isoflavonoid compounds and uses thereof |
| 02/04/2010 | WO2009148954A3 Tpo mimetic peptide for preventing hematological disorder associated with cancer treatment |
| 02/04/2010 | WO2009129208A3 Compositions and methods of inducing endoplasmic reticulum stress reponse |
| 02/04/2010 | WO2009103788A9 Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres |
| 02/04/2010 | WO2009068649A3 Antigen-binding constructs |
| 02/04/2010 | US20100029922 Platelet Derived Growth Factor (PDGF) Nucleic Acid Ligand Complexes |
| 02/04/2010 | US20100029766 Blends Comprising a Substituted Fatty Acid or a Derivative Thereof |
| 02/04/2010 | US20100029763 Methods to prepare penta-1,4-dien-3-ones and substituted cyclohexanones and derivatives with antitumoral and antiparasitic properties, the compounds and their uses |
| 02/04/2010 | US20100029758 Derivatives of isoflavones |
| 02/04/2010 | US20100029754 Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 |
| 02/04/2010 | US20100029752 Novel compounds, pharmaceutical compositions containing same, and methods of use for same |
| 02/04/2010 | US20100029749 Chimeric NK Receptor and Methods for Treating Cancer |
| 02/04/2010 | US20100029747 Methods and compositions for inhibiting the function of polynucleotide sequences |
| 02/04/2010 | US20100029744 Methods for Alzheimer's Disease Treatment and Cognitive Enhancement |
| 02/04/2010 | US20100029734 Methods for breast cancer screening and treatment |
| 02/04/2010 | US20100029731 Method for preparing largazole analogs and uses thereof |
| 02/04/2010 | US20100029719 Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors |
| 02/04/2010 | US20100029708 Compounds and compositions for treatment of cancer |
| 02/04/2010 | US20100029703 Anhydrous crystalline vinflunine salts, method of preparation and use thereof as a drug and means of vinflunine purification |
| 02/04/2010 | US20100029696 Indolylamino quinazoline derivatives as antitumor agents |
| 02/04/2010 | US20100029683 Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses |
| 02/04/2010 | US20100029673 Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use |
| 02/04/2010 | US20100029670 Organic compounds |
| 02/04/2010 | US20100029657 Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof |
| 02/04/2010 | US20100029649 Phenyl-substituted pyrimidine compounds useful as kinase inhibitors |
| 02/04/2010 | US20100029646 Prodrugs of diphenyl ox-indol-2-one compounds |
| 02/04/2010 | US20100029643 Heterocyclyc sulfonamides having edg-1 antagonistic activity |
| 02/04/2010 | US20100029642 Methods of Using Pyridodihydropyrazinones |
| 02/04/2010 | US20100029638 Fused heterocyclyc inhibitor compounds |
| 02/04/2010 | US20100029634 Chemokine Receptor Modulators |
| 02/04/2010 | US20100029633 Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors |
| 02/04/2010 | US20100029630 Reverse-turn mimetics and method relating thereto |
| 02/04/2010 | US20100029627 Mtki quinazoline derivatives |
| 02/04/2010 | US20100029622 Microemulsions |
| 02/04/2010 | US20100029610 Heteroaryl Compounds and Uses Thereof |
| 02/04/2010 | US20100029600 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain |
| 02/04/2010 | US20100029599 Indolylamides as modulators of the EP2 receptor |
| 02/04/2010 | US20100029598 Extended Benzamide Derivatives as Modulators of the EP2 Receptor |
| 02/04/2010 | US20100029594 Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin |
| 02/04/2010 | US20100029593 Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin |
| 02/04/2010 | US20100029585 Toll-like receptor agonist formulations and their use |
| 02/04/2010 | US20100029580 Method for Diagnosing Non-Small Cell Lung Carcinoma |
| 02/04/2010 | US20100029573 Tumor-associated peptides that bind to mhc-molecules |
| 02/04/2010 | US20100029557 Alpha-lactalbumin composition |
| 02/04/2010 | US20100029546 preparation method of galactosyl-has magnetic nanoparticles containing adriamycin |
| 02/04/2010 | US20100029484 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
| 02/04/2010 | US20100028905 Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto |
| 02/04/2010 | US20100028472 Herbal composition and process for its preparation |
| 02/04/2010 | US20100028461 Gamma-butyrolactone compound and pharmaceutical composition thereof |
| 02/04/2010 | US20100028460 Improvements in relation to cancer therapy |